Results 51 to 60 of about 3,081 (193)
Blood Cancer Journal, 2022 Constitutively activated B cell receptor (BCR) signaling is a primary biological feature of chronic lymphocytic leukemia (CLL). The biological events controlled by BCR signaling in CLL are not fully understood and need investigation. Here, by analysis of
Zhiquan Wang +15 more
doaj +1 more source
Bruton tyrosine kinase inhibitors and cardiovascular adverse events
British Journal of Pharmacology, EarlyView.Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli +4 more
wiley +1 more source
Economic Burden of Chronic Lymphocytic Leukaemia in Australia
European Journal of Haematology, EarlyView.ABSTRACT Background The treatment landscape for chronic lymphocytic leukaemia (CLL) has transformed over the past decade. This study aimed to estimate the healthcare costs and health burden associated with CLL in Australia. Methods A Markov model was developed to simulate the lifetime healthcare costs and health outcomes associated with CLL in ...
Lan Gao +4 more
wiley +1 more source
STRATEGI PENINGKATAN EKSPOR DENGAN MEMAKSIMALKAN INTELIJEN BISNIS DAN UTILISASI FORMAT BUKU TARIP KEPABEANAN INDONESIA (BTKI) [PDF]
, 2018 Increased export volume is always pursued by countries in the world. Increased export opportunities required optimal effort and efficient through Business Intelligence is an activity the ability to understand and understand a reciprocal relationship ...
Firdiansyah, Akhmad
core
, 2023 IntroductionBruton tyrosine kinase inhibitor (BTKi) has demonstrated substantial efficacy in treating B-cell lymphoproliferative diseases (BLPD). Nonetheless, the significant discontinuation rates due to toxicity or financial reasons cannot be overlooked.
Dehui Zou (9350856) +14 more
core +1 more source
, 2023 IntroductionBruton tyrosine kinase inhibitor (BTKi) has demonstrated substantial efficacy in treating B-cell lymphoproliferative diseases (BLPD). Nonetheless, the significant discontinuation rates due to toxicity or financial reasons cannot be overlooked.
Dehui Zou (9350856) +14 more
core +1 more source
Hemato, 2023 The dysregulation of the immune system in Chronic Lymphocytic Leukemia (CLL) often allows for the development of immune-mediated diseases. Among them, autoimmune cytopenias are the most common, but cases of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) have been reported.
Alessandro Cellini +5 more
openaire +4 more sources
Frontiers in Oncology, 2022 Primary central nervous system lymphoma (PCNSL) is a highly aggressive brain tumor with poor prognosis if no treatment. The activation of the NF-κB (nuclear factor kappa-B) is the oncogenic hallmark of PCNSL, and it was driven by B cell receptor (BCR ...
Jing Shen, Jinghua Liu, Jinghua Liu
doaj +1 more source
MedComm, Volume 7, Issue 10, October 2026.Proper myelin formation is crucial for normal neural circuit function, while myelin deficiency can lead to neural circuit dysfunction and cognitive decline, notably in Alzheimer's disease and other central nervous system demyelinating disorders. This review summarizes central myelin's structure and function, demyelination biomarkers and pathological ...
Lihong Huang +5 more
wiley +1 more source
, 2023 IntroductionBruton tyrosine kinase inhibitor (BTKi) has demonstrated substantial efficacy in treating B-cell lymphoproliferative diseases (BLPD). Nonetheless, the significant discontinuation rates due to toxicity or financial reasons cannot be overlooked.
Dehui Zou (9350856) +14 more
core +1 more source